Sustained reduction in myocardial reperfusion injury with an adenosine receptor antagonist: Possible role of the neutrophil chemoattractant response

Mervyn B. Forman, João V. Vitola, Carlos E. Velasco, John J. Murray, Raghvendra K. Dubey, Edwin K. Jackson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Recent studies have demonstrated that three membrane-permeant A1 receptor antagonists reduced infarct size in a model of ischemia followed by brief reperfusion. However, it was not determined whether cardioprotection was mediated by nonspecific intracellular effects of these highly lipophilic drugs and whether the antagonists only delayed myocardial necrosis without affecting the ultimate infarct size. In the present study, closed-chest dogs were subjected to 90 min of left anterior descending coronary artery occlusion and 72 h of reperfusion add received either a nonmembrane-permeant adenosine receptor blocker that is devoid of direct intracellular effects and is 6-fold selective for the A1 receptor [1,3-dipropyl-8-p- sulfophenylxanthine (DPSPX); n = 11] or vehicle (n = 12). DPSPX was administered as three 200-mg boluses 60 min before and 30 and 120 min after reperfusion. The area of necrosis was determined histologically and expressed as a percentage of the area at risk. Baseline predictors of infarct size were similar in the two groups. The ratio of the area of necrosis to the area at risk was less in the DPSPX group (17.8 ± 4.3% versus 35.0 ± 1.9%; P = .012), and DPSPX improved regional ventricular function. Under both basal and stimulated (formyl-Met-Leu-Phe) conditions, suspensions of human neutrophils generated extracellular adenosine levels (approximately 50 nM) sufficient to activate A1 receptors. Moreover, both DPSPX and 1,3-dipropyl-8- cyclopentylxanthine, a selective A1 receptor antagonist, significantly reduced the chemoattractant response of neutrophils to formyl-Met-Leu-Phe. We conclude that blockade of A1 adenosine receptors attenuates myocardial ischemic/reperfusion injury, possibly in part by decreasing the chemoattractant response of neutrophils.

Original languageEnglish (US)
Pages (from-to)929-938
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume292
Issue number3
StatePublished - Mar 1 2000

Fingerprint

Purinergic P1 Receptor Antagonists
Myocardial Reperfusion Injury
Chemotactic Factors
methionyl-leucyl-phenylalanine
Reperfusion
Neutrophils
Necrosis
Adenosine A1 Receptors
Purinergic P1 Receptors
Ventricular Function
Coronary Occlusion
Adenosine
Coronary Vessels
Suspensions
Thorax
Ischemia
Dogs
Membranes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Molecular Medicine
  • Pharmacology

Cite this

Sustained reduction in myocardial reperfusion injury with an adenosine receptor antagonist : Possible role of the neutrophil chemoattractant response. / Forman, Mervyn B.; Vitola, João V.; Velasco, Carlos E.; Murray, John J.; Dubey, Raghvendra K.; Jackson, Edwin K.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 292, No. 3, 01.03.2000, p. 929-938.

Research output: Contribution to journalArticle

Forman, Mervyn B. ; Vitola, João V. ; Velasco, Carlos E. ; Murray, John J. ; Dubey, Raghvendra K. ; Jackson, Edwin K. / Sustained reduction in myocardial reperfusion injury with an adenosine receptor antagonist : Possible role of the neutrophil chemoattractant response. In: Journal of Pharmacology and Experimental Therapeutics. 2000 ; Vol. 292, No. 3. pp. 929-938.
@article{1a1a37341f684882b8b3fc31efb08d95,
title = "Sustained reduction in myocardial reperfusion injury with an adenosine receptor antagonist: Possible role of the neutrophil chemoattractant response",
abstract = "Recent studies have demonstrated that three membrane-permeant A1 receptor antagonists reduced infarct size in a model of ischemia followed by brief reperfusion. However, it was not determined whether cardioprotection was mediated by nonspecific intracellular effects of these highly lipophilic drugs and whether the antagonists only delayed myocardial necrosis without affecting the ultimate infarct size. In the present study, closed-chest dogs were subjected to 90 min of left anterior descending coronary artery occlusion and 72 h of reperfusion add received either a nonmembrane-permeant adenosine receptor blocker that is devoid of direct intracellular effects and is 6-fold selective for the A1 receptor [1,3-dipropyl-8-p- sulfophenylxanthine (DPSPX); n = 11] or vehicle (n = 12). DPSPX was administered as three 200-mg boluses 60 min before and 30 and 120 min after reperfusion. The area of necrosis was determined histologically and expressed as a percentage of the area at risk. Baseline predictors of infarct size were similar in the two groups. The ratio of the area of necrosis to the area at risk was less in the DPSPX group (17.8 ± 4.3{\%} versus 35.0 ± 1.9{\%}; P = .012), and DPSPX improved regional ventricular function. Under both basal and stimulated (formyl-Met-Leu-Phe) conditions, suspensions of human neutrophils generated extracellular adenosine levels (approximately 50 nM) sufficient to activate A1 receptors. Moreover, both DPSPX and 1,3-dipropyl-8- cyclopentylxanthine, a selective A1 receptor antagonist, significantly reduced the chemoattractant response of neutrophils to formyl-Met-Leu-Phe. We conclude that blockade of A1 adenosine receptors attenuates myocardial ischemic/reperfusion injury, possibly in part by decreasing the chemoattractant response of neutrophils.",
author = "Forman, {Mervyn B.} and Vitola, {Jo{\~a}o V.} and Velasco, {Carlos E.} and Murray, {John J.} and Dubey, {Raghvendra K.} and Jackson, {Edwin K.}",
year = "2000",
month = "3",
day = "1",
language = "English (US)",
volume = "292",
pages = "929--938",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Sustained reduction in myocardial reperfusion injury with an adenosine receptor antagonist

T2 - Possible role of the neutrophil chemoattractant response

AU - Forman, Mervyn B.

AU - Vitola, João V.

AU - Velasco, Carlos E.

AU - Murray, John J.

AU - Dubey, Raghvendra K.

AU - Jackson, Edwin K.

PY - 2000/3/1

Y1 - 2000/3/1

N2 - Recent studies have demonstrated that three membrane-permeant A1 receptor antagonists reduced infarct size in a model of ischemia followed by brief reperfusion. However, it was not determined whether cardioprotection was mediated by nonspecific intracellular effects of these highly lipophilic drugs and whether the antagonists only delayed myocardial necrosis without affecting the ultimate infarct size. In the present study, closed-chest dogs were subjected to 90 min of left anterior descending coronary artery occlusion and 72 h of reperfusion add received either a nonmembrane-permeant adenosine receptor blocker that is devoid of direct intracellular effects and is 6-fold selective for the A1 receptor [1,3-dipropyl-8-p- sulfophenylxanthine (DPSPX); n = 11] or vehicle (n = 12). DPSPX was administered as three 200-mg boluses 60 min before and 30 and 120 min after reperfusion. The area of necrosis was determined histologically and expressed as a percentage of the area at risk. Baseline predictors of infarct size were similar in the two groups. The ratio of the area of necrosis to the area at risk was less in the DPSPX group (17.8 ± 4.3% versus 35.0 ± 1.9%; P = .012), and DPSPX improved regional ventricular function. Under both basal and stimulated (formyl-Met-Leu-Phe) conditions, suspensions of human neutrophils generated extracellular adenosine levels (approximately 50 nM) sufficient to activate A1 receptors. Moreover, both DPSPX and 1,3-dipropyl-8- cyclopentylxanthine, a selective A1 receptor antagonist, significantly reduced the chemoattractant response of neutrophils to formyl-Met-Leu-Phe. We conclude that blockade of A1 adenosine receptors attenuates myocardial ischemic/reperfusion injury, possibly in part by decreasing the chemoattractant response of neutrophils.

AB - Recent studies have demonstrated that three membrane-permeant A1 receptor antagonists reduced infarct size in a model of ischemia followed by brief reperfusion. However, it was not determined whether cardioprotection was mediated by nonspecific intracellular effects of these highly lipophilic drugs and whether the antagonists only delayed myocardial necrosis without affecting the ultimate infarct size. In the present study, closed-chest dogs were subjected to 90 min of left anterior descending coronary artery occlusion and 72 h of reperfusion add received either a nonmembrane-permeant adenosine receptor blocker that is devoid of direct intracellular effects and is 6-fold selective for the A1 receptor [1,3-dipropyl-8-p- sulfophenylxanthine (DPSPX); n = 11] or vehicle (n = 12). DPSPX was administered as three 200-mg boluses 60 min before and 30 and 120 min after reperfusion. The area of necrosis was determined histologically and expressed as a percentage of the area at risk. Baseline predictors of infarct size were similar in the two groups. The ratio of the area of necrosis to the area at risk was less in the DPSPX group (17.8 ± 4.3% versus 35.0 ± 1.9%; P = .012), and DPSPX improved regional ventricular function. Under both basal and stimulated (formyl-Met-Leu-Phe) conditions, suspensions of human neutrophils generated extracellular adenosine levels (approximately 50 nM) sufficient to activate A1 receptors. Moreover, both DPSPX and 1,3-dipropyl-8- cyclopentylxanthine, a selective A1 receptor antagonist, significantly reduced the chemoattractant response of neutrophils to formyl-Met-Leu-Phe. We conclude that blockade of A1 adenosine receptors attenuates myocardial ischemic/reperfusion injury, possibly in part by decreasing the chemoattractant response of neutrophils.

UR - http://www.scopus.com/inward/record.url?scp=0034008519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034008519&partnerID=8YFLogxK

M3 - Article

C2 - 10688606

AN - SCOPUS:0034008519

VL - 292

SP - 929

EP - 938

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -